Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106 is registered in ClinicalTrials.gov with Abeona Therapeutics, Inc as lead sponsor.

NCT NCT04227106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04227106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Lead sponsor
Abeona Therapeutics, Inc
Phase
Phase 3
Overall status
Completed
Start date
January 10, 2020
Completion date
October 18, 2022
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa, recessive dystrophic epidermolysis bullosa